Papers on fezolinetant
60 papers8 new in 30 days
Wednesday, November 18
Tuesday, November 17
International Journal of Innovative Technologies in Social Science
EFFICACY AND SAFETY OF NON-HORMONAL NK- 3 RECEPTOR ANTAGONISTS FOR VASOMOTOR SYMPTOMS OF MENOPAUSE: A SYSTEMATIC REVIEW
Systematic review of studies in peopleVasomotor symptoms
Wednesday, November 11
PLOS Genetics
Tachykinin-like NLP-58 signaling through TKR-1 modulates thermotaxis behavior in Caenorhabditis elegans

Experiments in wormsMechanisms
Monday, November 9
Sunday, November 1
Thursday, October 22
Revista Ibero-Americana de Humanidades, Ciências E Educação
PSYCHOPHARMACOLOGY IN THE CLIMACTERIC, MENOPAUSE, AND LATE MENOPAUSE: EVIDENCE, GOLD STANDARDS, AND EQUITY IN ACCESS TO TREATMENT IN WOMEN 40+
Sunday, October 18
Research Society and Development
Neurokinin receptor antagonists in the treatment of menopausal vasomotor symptoms: Efficacy, safety, and impact on sleep and quality of life
Systematic reviewNeurokinin receptor antagonists
Wednesday, October 14
Menopause
Quantitative assessment of neurokinin receptor antagonists in menopausal hot flashes: a model-based meta-analysis
Meta-analysis of randomized trialsHot flashes
Tuesday, October 6
Annals of Internal Medicine
Pharmacologic Treatments for Female Menopausal Vasomotor Symptoms: A Systematic Review and Meta-analysis for the American College of Physicians
Meta-analysis of randomized trialsMenopausal vasomotor symptoms
Monday, September 14
Climacteric
Effect of fezolinetant on sleep, health-related quality of life and work productivity
Randomized trial in peopleFezolinetant
Wednesday, August 19
Clinical and Experimental Obstetrics & Gynecology
Contemporary Management of Menopausal Vasomotor Symptoms: An Evidence-Based Review of Hormonal and Non-Hormonal Interventions
ReviewVasomotor symptoms
Tuesday, August 4
Naunyn-Schmiedeberg's Archives of Pharmacology
Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database
Cross-sectional study of 1,757 peopleFezolinetant
Tuesday, July 28
Obstetrics and Gynecology Clinics of North America
Neurokinin 3 Receptor Antagonists for Menopause Symptom Management
ReviewVasomotor symptoms
Thursday, July 9
Revista de Obstetricia y Ginecología de Venezuela
Neurokinin 3 receptor antagonists (fezolinetant) for the treatment of vasomotor symptoms of menopause. Systematic review
Systematic review of randomized trialsFezolinetant
Thursday, May 21
Friday, May 15
Journal of the Endocrine Society
Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications
ReviewFezolinetant
Friday, May 8
International Journal of Drug Delivery Technology
Precision Pharmacological Stratification and Targeted Management of Pathological Menopause: Evidence-Based Hormone Replacement Therapy Optimization, Non-Hormonal Pharmacotherapy, and Personalized Strategies in Premature Ovarian Insufficiency and Iatrogenic Forms
Systematic reviewEarly menopause
Wednesday, April 29
Universitas Médica
Fezolinetant: neurokinin 3 (NK3) receptor antagonist for the treatment of menopausal vasomotor symptoms
Systematic reviewFezolinetant
Tuesday, April 28
Friday, April 3
Women's Health
Fezolinetant treatment for hot flashes associated with menopause: A plain language summary of the DAYLIGHT study
Randomized trial in peopleFezolinetant
Tuesday, March 31
Tuesday, March 24
Wednesday, March 18
Drug Safety
Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant
Meta-analysis of randomized trialsElinzanetant
Monday, March 16
Saturday, February 14
International Seven Journal of Multidisciplinary
THERAPEUTIC MANAGEMENT OF MENOPAUSE: HORMONAL APPROACH AND NON-HORMONAL ALTERNATIVES
Friday, January 16
Clinical Pharmacology and Therapeutics
Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant
Computational studyFezolinetant
